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Abstract
Recent studies have revealed that TRH-like immunore-
activity (TRH-LI) in human serum is predominantly
pGlu-Glu-ProNH2 (<EEP-NH2), a peptide previously
found in, among others tissues, the pituitary gland of
various mammalian species. In the rat pituitary, <EEP-
NH2 is present in gonadotrophs and its pituitary content is
regulated by gonadal steroids and gonadotrophin-releasing
hormone (GnRH). Hence, we reasoned that <EEP-NH2
in human serum may also arise, at least in part, from the
pituitary, and that its secretion may correlate with that
of gonadotrophins. Therefore, blood was simultaneously
sampled from both inferior petrosal sinuses, which are
major sites of the venous drainage of the pituitary gland,
and a peripheral vein from seven patients with suspected
adrenocorticotrophin-secreting pituitary tumours. In
addition, in six postmenopausal and six cyclic women,
peripheral vein blood was collected at 10-min intervals for
6 h, then a standard 100 µg GnRH test was performed. In
the sera, TRH-LI was estimated by RIA with antiserum
4319, which binds most tripeptides that share the N- and
C-terminal amino acids with TRH (pGlu-His-ProNH2).
In addition, LH and FSH were measured in these sera by
RIA. In the blood samples taken at 10-min intervals, an
episodic variation in serum TRH-LI was noted and pulses
of TRH-LI were detected at irregular intervals (from one
to six pulses per 6 h) in five postmenopausal and six cyclic
women. In general, these pulses did not coincide with
those of LH and FSH, suggesting that TRH-LI is not
co-secreted with gonadotrophins. Moreover, unlike LH
and FSH, serum TRH-LI did not increase during the
menopause or after exogenous administration of GnRH.
Whereas gonadotrophin concentrations were significantly
greater in the inferior petrosal sinus than in peripheral
serum, there were no diVerences in TRH-LI concen-
trations between these serum samples. In conclusion,
serum TRH-LI in humans seems not to be regulated by
gonadal steroids or GnRH. Moreover, serum derived
directly from the pituitary contained no more TRH-LI
than did peripheral serum, which suggests that the human
pituitary gland does not secrete significant amounts of
<EEP-NH2, and therefore does not contribute signifi-
cantly to serum TRH-LI concentrations. Further research
is required to identify the site of origin of <EEP-NH2 in
human serum.
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Introduction
Thyrotrophin-releasing hormone (TRH) was originally
isolated from hypothalamic extracts. Subsequently, TRH-
like immunoreactivity (TRH-LI) was detected in periph-
eral tissues, blood and urine (for reviews, see Ho¨kfelt et al.
1989, Ashworth 1994, Iversen 1995). Although TRH-LI
in the brain and certain peripheral tissues has been
identified as authentic TRH (Pekary et al. 1980, 1993,
Ashworth 1994, Iversen 1995, Klootwijk et al. 1997a),
TRH-LI in other tissues is attributable to peptides that are
structurally related to TRH (Cockle et al. 1989, Khan et al.
1992, Ashworth 1994, Gkonos et al. 1994, Cockle 1995,
Rondeel et al. 1995a,b, Linden et al. 1996). These
TRH-like peptides, which diVer from TRH (pGlu-
His-ProNH2) in the middle amino acid, cross-react to
varying extents with antisera raised against TRH (Pekary
et al. 1993, Rondeel et al. 1995a, Klootwijk et al. 1995,
1996). The knowledge of the function of these TRH-like
peptides remains limited, but physiological actions have
been reported for pGlu-Glu-ProNH2 (<EEP-NH2), a
peptide detected first in the prostate gland (Cockle et al.
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1989) and later in semen and the anterior pituitary gland of
various mammalian species (for reviews, see Ashworth
1994, Cockle 1995), in a human neuroblastoma cell line
(Rondeel et al. 1994) and in serum and urine of patients
with metastatic carcinoid tumours (Klootwijk et al. 1996,
1997b). Recently, <EEP-NH2 has been found to enhance
the fertilizing ability of human and mouse sperm (Green
et al. 1994, 1996a), to inhibit the acrosome reaction of
mouse sperm (Green et al. 1996b), to increase the motility
of sperm from certain infertile men (Linden et al. 1996), to
aVect pituitary growth hormone release in domestic fowls
and rats (Harvey et al. 1993, Ashworth et al. 1994,
Rondeel et al. 1995b) and to inhibit adrenal corticosterone
secretion in rats (Neri et al. 1993). Because of its eVect
on sperm, <EEP-NH2 has also been called fertilization
promoting peptide (FPP, Cockle 1995).
Serum of healthy humans also contains TRH-LI that is
not identical to TRH (Iversen 1986), and recent data
show that the predominant TRH-like peptide in human
and rat serum is <EEP-NH2 (Bertram & Cockle 1995,
Klootwijk et al. 1997a,b). Although prostatic secretion of
<EEP-NH2 may contribute to serum concentrations of
TRH-LI in men (Bertram & Cockle 1995, Klootwijk et al.
1997b), the similarity of serum TRH-LI in men and
women (Klootwijk et al. 1996, 1997b) indicates that other
sources of <EEP-NH2 exist. Studies in rats have provided
suggestive evidence that <EEP-NH2 in the pituitary
gland is produced by the gonadotrophs (Rondeel et al.
1995a,b), and have revealed that the pituitary content of
<EEP-NH2 is influenced by treatments aVecting gonado-
trophin release (Akinsanya et al. 1995, Rondeel et al.
1995a,b). We have studied the possibility that, in human
serum, <EEP-NH2 is derived at least in part from
hypophysial secretion, and that this secretion is correlated
with that of gonadotrophins.
Study participants and methods
All studies were performed according to the rules of the
respective medical ethics committees of the University
Hospitals of Amsterdam and Rotterdam.
Profiles of TRH-LI and gonadotrophins in peripheral serum of
postmenopausal and cyclic women
Twelve healthy women volunteers, six postmenopausal
(aged 52–72 years, median 57 years) and six premeno-
pausal women at day 3 of the menstrual cycle (ages 32–38
years, median 36 years), participated in the study. A
cannula was placed in a peripheral vein at between 0800
and 0900 h, and blood samples were removed from
the cannula every 10 min for 6 h. At the end of the 6 h
period, 100 µg gonadotrophin-releasing hormone (GnRH;
Wyeth, Hoofddorp, The Netherlands) was injected
through the cannula and additional blood samples were
taken 30, 60 and 90 min later. Blood was allowed to clot
and serum was kept at room temperature for at least 2 h to
ensure the enzymatic degradation of any endogenous
TRH-LI that was not identical to <EEP-NH2 (Cockle
et al. 1994, Klootwijk et al. 1997b) by serum pyroglutamyl
aminopeptidase II (Schauder et al. 1994). The serum
samples were stored at "20 )C until required for
analysis for TRH-LI, luteinizing hormone (LH) and
follicle-stimulating hormone (FSH) by RIA.
Concentrations of TRH-LI and gonadotrophins in peripheral
and inferior petrosal sinus serum
Synchronous blood samples were obtained from both
inferior petrosal sinuses and from a peripheral vein as
described previously (de Herder et al. 1994), for the
Table 1 Characteristics of TRH-LI, LH and FSH in serum of postmenopausal (n=6) and
premenopausal (n=6) women. Blood was taken from these volunteers at 10-min intervals





Mean concentration (pg/ml) 16·4&1·7 21·6&3·0
Mean amplitude (pg/ml) 13·3&1·3 17·1&2·4
Pulses per 6 h 2·7&1·0 3·3&0·7
LH
Mean concentration (mU/ml) 19·2&3·1 3·2&0·8*
Mean amplitude (mU/ml) 4·1&0·4 1·1&0·3*
Pulses per 6 h 4·3&0·3 4·5&0·3
FSH
Mean concentration (mU/ml) 68·1&11·4 7·3&1·7*
Mean amplitude (mU/ml) 6·4&1·5 1·0&0·3*
Pulses per 6 h 4·7&0·7 3·2&0·5
*P<0·05 compared with postmenopausal women.
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diagnosis of pituitary-dependent Cushing’s disease in four
women (aged 25–73 years, median 40 years) and three
men (aged 28–66 years, median 63 years). Blood was
removed before (0 min) and several times after stimulation
with corticotrophin-releasing hormone (CRH, 1 µg/kg,
Bissendorf Peptide Pharmaentwicklung und Vertrieb
GmbH, Hannover, Germany) to evaluate the response of
adrenocorticotrophin (de Herder et al. 1994). On the basis
of the resulting serum concentrations of adrenocortico-
trophin, four of these patients were found to have
Cushing’s disease. Retrospectively, it was found that two
patients did not suVer from Cushing’s syndrome, but
had generalized obesity, and one had an adrenal cortisol-
secreting adenoma. The blood samples were treated as
described above, and the sera were stored at "20 )C
until required for analysis.
Assays
All samples from each participant were estimated at least in
duplicate in the same assay. Concentrations of TRH-LI
were determined in unextracted serum by RIA with
antiserum 4319, an antiserum which detects most TRH-
like peptides that diVer from TRH by the central amino
acid – i.e. peptides with the structure pGlu-X-ProNH2
(Rondeel et al. 1995a, Klootwijk et al. 1995, 1996).
Antiserum 4319 was used at a final dilution of 1:20 000 in
the RIA, using 125I-TRH as tracer and unlabelled TRH
as standard. The limit of detection for this assay is 3–5 pg
TRH/ml, and the intra- and interassay coeYcients of
variation were less than 15%. Previously, we provided
evidence that most TRH-LI in human serum kept at room
temperature for at least 2 h is accounted for by <EEP-
NH2 (Klootwijk et al. 1997b). In this paper, however, we
nevertheless present the data as TRH-LI, expressed as
TRH equivalents, because minor contributions from other
TRH-like peptides cannot be excluded.
In the samples collected at 10-min intervals, LH
and FSH were measured by a double antibody
IRMA (IRMA-mat BYK-Sangtec Diagnostica GmbH,
Dietzenbach, Germany). In inferior petrosal sinus and
corresponding peripheral serum samples, gonadotrophins
Figure 1 Patterns of serum concentrations of TRH-LI in individual postmenopausal women.
Blood samples were taken every 10 min for 6 h. -, nadir of detected TRH-LI pulses;
arrows indicate the occurrence of LH pulses.
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were estimated using an immunometric method with an
enhanced luminescence endpoint (Amerlite; Johnson &
Johnson Clinical Diagnostics, Amersham, UK). The lower
limits of detection of the gonadotrophin assays were less
than 0·2 IU/l, and references for expression of LH and
FSH were first IRP 68/40 and second IRP 78/549,
respectively; the intra- and interassay coeYcients of
variation were less than 8%.
Pulse detection of serum TRH-LI, LH and FSH was
performed as described previously (Lambalk et al. 1985,
Scheele et al. 1987). The algorithm of the analysis is valid
for replicates of repeated measurements with a chance of
less than 5% to indicate non-existing pulses as a pulse in a
series of 100 samples taken from pooled serum. Nadirs
preceding the pulses, rather than the pulses themselves,
were used for analyses of the hormone patterns. Pulses of
TRH-LI, LH and FSH were considered to be asynchro-
nous when they started more than 10 min apart (Veldhuis
et al. 1991). The maximum gonadotrophin and TRH-LI
increments were taken as the measure of their response
to GnRH.
Statistical analyses
Results are given as means&s.e.m., and statistical tests
included analysis of variance, Wilcoxon matched-pairs
signed-ranks test and linear regression analysis. P¦0·05
was considered significant.
Results
Small but measurable amounts of TRH-LI were detected
in the serum samples. Isocratic reverse-phase high per-
formance liquid chromatography revealed that most
TRH-LI in serum of normal volunteers co-eluted with
<EEP-NH2 (data not shown). Mean serum concentrations
of TRH-LI were found to be similar in cyclic and
postmenopausal women, whereas serum concentrations of
LH and FSH were greater in postmenopausal than in
cyclic women (Table 1). An episodic variation in serum
TRH-LI was observed and, in 11 women, pulses of
TRH-LI were detected at irregular intervals (Figs 1 and
2). In these women, pulses occurred between one and
Figure 2 Patterns of serum concentrations of TRH-LI in individual fertile women on day 3
of the menstrual cycle. Blood samples were taken every 10 min for a period of 6 h.
-, nadir of detected TRH-LI pulses; arrows indicate the occurrence of LH pulses.
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six times during the period of observation, with a mean
of about three pulses per 6 h (Table 1). The pulses of
TRH-LI in these female volunteers in general did not
coincide with pulses of LH (Figs 1 and 2) or FSH (data not
shown). Whereas serum concentrations of LH and FSH
increased significantly in all women in response to 100 µg
GnRH (LH: 376&28%, FSH: 152&4%; P<0·01), no
significant eVect of GnRH on serum TRH-LI was
observed (122&16%).
As expected, a significant correlation (r=0·80, P<0·01)
was found between serum LH and FSH during the 6-h
period of observation. In contrast, serum concentrations of
TRH-LI and FSH, averaged over the 6-h period, did not
correlate significantly (r="0·42; P=0·18). An almost
significant inverse correlation was observed between the
mean TRH-LI and LH concentrations (r="0·55;
P=0·06). Because of this possible negative relation, we
evaluated whether peaks of TRH-LI pulses occurred
within 10 min of the nadir of an LH pulse; however, this
proved to be the case with only six of 36 TRH-LI pulses.
TRH-LI concentrations were found to be similar in
serum obtained from the inferior petrosal sinuses or from a
peripheral vein of the two obese patients (Fig. 3), the four
patients suVering from pituitary-dependent Cushing’s
disease (Fig. 4 shows data for two of them) and the patient
with a cortisol-secreting adenoma (data not shown). Dur-
ing the period of observation, concentrations of TRH-LI
in inferior sinus petrosus serum of these seven subjects
were 94&3% of those in peripheral serum. In contrast,
concentrations of LH and FSH were significantly greater
in inferior sinus petrosus serum than in peripheral serum
(LH: 205&23%, FSH: 121&6%; P<0·025). Similar
findings were made for growth hormone and prolactin
(data not shown), and during the sampling period the
concentrations of these hormones in inferior sinus petrosus
serum were, respectively, 997&63% and 470&99%
Figure 3 Concentrations of TRH-LI, LH and FSH in serum of two
obese patients, obtained by simultaneous blood sampling of a
peripheral vein (open bar) and the left (,) and right (-) inferior
petrosal sinuses. Left: results from a 63-year-old man. Right: results
from a 35-year-old woman using oral contraceptives.
Figure 4 Concentrations of TRH-LI, LH and FSH in serum of two
patients with pituitary-dependent Cushing’s disease, obtained by
simultaneous blood sampling of a peripheral vein (open bar) and
the left (,) and right (-) inferior petrosal sinuses. Left: results
from a 73-year-old woman. Right: results from a 66-year-old man.
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greater (P<0·025) than the values measured in peripheral
serum.
Discussion
This study concerned the presence, in human serum, of
TRH-LI, concentrations of which in women were found
to exhibit episodic variations. Recent data have revealed
that the predominant TRH-LI in serum of normal human
subjects is <EEP-NH2 (Bertram & Cockle 1995,
Klootwijk et al. 1996, 1997b, present study), and similar
findings have been made for rat serum (Klootwijk et al.
1997a). Because <EEP-NH2 in the rat pituitary gland is
probably synthesized by gonadotrophin-secreting cells and
is regulated in a ‘gonadotrophic’ manner (Akinsanya 1995,
Rondeel et al. 1995a,b), we hypothesized that TRH-LI
in human serum originates at least in part from the
pituitary gland and correlates with the secretion pattern of
gonadotrophins. Our objective was to test this hypothesis.
Concentrations of TRH-LI were found to be similar in
blood samples simultaneously obtained from both inferior
petrosal sinuses, which are major sites of venous drainage
of the anterior pituitary gland, and from a peripheral vein.
Thus serum derived directly from the pituitary gland does
not contain more TRH-LI than peripheral serum. This
observation suggests that the pituitary gland does not
secrete significant amounts of <EEP-NH2. Because
petrosal sinus sampling was performed in patients
with suspected adrenocorticotrophin-secreting pituitary
tumours, it cannot be excluded that the presence of such
tumours could have resulted in the impaired secretion of
TRH-LI from the pituitary gland. However, because LH
and FSH concentrations were significantly greater in sinus
petrosus serum than in peripheral serum during the period
of observation, it seems unlikely that the presence of
adenomas prevented the pituitary release of TRH-LI.
Moreover, in two obese patients without a tumour,
TRH-LI concentrations were similar in sinus petrosus and
peripheral serum.
The lack of diVerence between TRH-LI concentrations
in sinus petrosus and peripheral serum may also be
explained by a long half-life of <EEP-NH2 in blood,
which would mask potential pituitary secretion of this
peptide. In rats, the disappearance of <EEP-NH2 from
serum (Klootwijk et al. 1997a) is comparable to that of
FSH and LH (de Greef et al. 1983), and intravenously
injected <EEP-NH2 could be recovered unchanged and
quantitatively in urine (Klootwijk et al. 1997a). In humans
also, serum <EEP-NH2 is cleared by renal excretion and
its urinary clearance rate is similar to the glomerular
filtration rate (Klootwijk et al. 1997b). Thus these data
suggest that the similar TRH-LI concentrations in sinus
petrosus and peripheral serum are not caused by a long
half-life of <EEP-NH2.
We also investigated whether TRH-LI was co-secreted
with LH or FSH in healthy female volunteers. Although
serum concentrations of TRH-LI were found to fluctuate,
the pulses were not synchronous with those of LH or FSH,
but rather, an almost significant inverse correlation was
found between the mean TRH-LI and LH concen-
trations. These findings indicate that, at least in human
females, TRH-LI is probably not co-secreted with
gonadotrophins.
Because the <EEP-NH2 content in rat pituitary is
aVected by both gonadectomy and GnRH (Akinsanya
et al. 1995, Rondeel et al. 1995a,b), we also analysed the
eVect of menopause and GnRH on serum TRH-LI in
women. Although serum concentrations of LH and FSH
were greater in postmenopausal than in cyclic women,
TRH-LI values were similar in both groups of women.
Moreover, whereas administration of GnRH invariably
increased serum concentrations of LH and FSH in both
cyclic and postmenopausal women, no consistent acute
eVect of GnRH on serum TRH-LI was observed.
In conclusion, serum TRH-LI was found to exhibit an
episodic variation. Although <EEP-NH2 has been found
in the anterior pituitary gland of various mammalian
species (Cockle 1995), our observations do not provide
evidence that, in humans, hypophysial secretion of <EEP-
NH2 contributes significantly to serum concentrations of
TRH-LI. Thus further research is required to identify the
site of origin of <EEP-NH2 in human serum.
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